OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. Approximately 25% of patients present metastatic disease at diagnosis and about 50% will develop metastatic disease. Patients with metastatic colorectal cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treatments, including monoclonal antibodies as first or second-line regimens. Use of bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. Considering the emerging data, it is important to understand these implications in terms of costs for the Brazilian private healthcare system. Our objectives were to compare economic outcomes of different sequences of therapy including monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios were analyzed, each one comparing different treatment sequences. A sequence of bevacizumab TML (first-line and beyond first progression) was compared in each scenario with another sequence without bevacizumab TML. To compare the economic outcomes, the monthly cost and the total cost of the sequence per patient were calculated, according to the first, second and third-lines combinations. RESULTS: Considering a standard time of treatment of 12.8 months and progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevacizumab TML were less costly than multiple lines without bevacizumab.  The lowest monthly cost was related to bevacizumab TML (1^stline bevacizumab 5mg+FOLFOX → 2^ndline bevacizumab 5mg+FOLFIRI → 3^rdline best supportive care [BSC]). This sequence represents a monthly cost of R$ 18,192.41 per patient while the same scenario with cetuximab in first-line (1^stline cetuximab 250mg+FOLFIRI → 2^ndline bevacizumab 10mg+FOLFOX → 3^rdline BSC) represents R$ 23,640.57 per month/patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared with sequences of biological therapy that starts with cetuximab in the first-line followed by bevacizumab in second-line treatment. Resource savings with sequential bevacizumab have the potential to optimize third-line treatment strategy for mCRC patients with wild-type KRAS in Brazil.